Skip to main content

Prostate Cancer Clinical Trials

Review the prostate cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 276-300 of 514

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Status: Active
Location: See ClinicalTrials.gov
Evaluation of AP-002 in Patients With Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Status: Active
Location: 2 locations
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating MM-310 in Patients With Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Total Eradication following Radiation for the Treatment of Oligometastatic Prostate Cancer, TERPS Study
Status: Enrolling by Invitation
Location: 10 locations
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov
Abiraterone and Prednisone with Standard ADT versus Standard ADT Alone in Treating Prostate Cancer Patients
Status: Approved
Location: University of Nebraska Medical Center, Omaha, Nebraska
PSMA-PET Guided De-escalated Radiation Therapy for the Treatment of Recurrent Prostate Cancer after Radical Prostatectomy
Status: Approved
Location: University of Nebraska Medical Center, Omaha, Nebraska
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Robot-Assisted Radical Prostatectomy with or without Vesicopexy in Patients with Prostate Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
Surgical Removal of Prostate Tumor and Antiandrogen Therapy with or without Docetaxel in Treating Men with Newly Diagnosed Metastatic Prostate Cancer
Status: Temporarily Closed to Accrual
Location: 18 locations
Vidutolimod (CMP-001) in Combination with Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Status: Temporarily Closed to Accrual
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
Status: Temporarily Closed to Accrual
Location: 2 locations
Hypofractionated Proton Beam Radiation Therapy in Treating Patients with Localized Prostate Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Evaluation of 177Lu rhPSMA-10.1 and Degarelix before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer, Nautilus Trial
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Copanlisib in Combination with Degarelix in Treating High-Risk Localized Prostate Cancer prior to Radical Prostatectomy, The CHARIOT Trial
Status: Temporarily Closed to Accrual
Location: 7 locations
Autophagy Therapeutics (Hydroxychloroquine, Nelfinavir, Metformin, Dasatinib, and Sirolimus) for the Treatment of Advanced Solid Tumors or Relapsed Prostate Cancer
Status: Temporarily Closed to Accrual
Location: Medical University of South Carolina, Charleston, South Carolina
Pegargiminase (ADI-PEG 20), Carboplatin, and Cabazitaxel for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care
Status: Temporarily Closed to Accrual
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 for the Treatment of Prostate Adenocarcinoma, LUTACT Trial
Status: Temporarily Closed to Accrual
Location: University of California San Francisco, San Francisco, California
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov